CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
CIP2A is a recently characterized oncoprotein which involves in the progression of several human malignancies. This study aimed to investigate its clinical significance and biological function in ovarian cancer. CIP2A expression was analyzed in 152 archived ovarian cancer specimens using immunohistochemistry. One hundred cases (65.79 %) showed CIP2A overexpression, including 63 of 92 serous carcinomas (68.48 %), 21 of 33 endometrioid carcinomas (63.64 %), 12 of 23 mucinous carcinomas (52.17 %), and 4 of 4 clear cell carcinomas (100 %). There is no significant difference of CIP2A expression between serous tumors and all other morphologies combined. CIP2A overexpression positively correlated with advanced FIGO stage (p = 0.0336) and tumor grade (p = 0.0213). siRNA knockdown was performed in A2780 and SKOV3 cell lines. MTT, colony formation assay, and flow cytometry were carried out to assess the role of CIP2A in proliferation, cell cycle, and apoptosis. CIP2A depletion in ovarian cancer cell lines inhibited proliferation, blocked cell cycle progression, and increased paclitaxel-induced apoptosis. Furthermore, CIP2A depletion downregulated cyclin D1, c-myc, phospho-Rb, Bcl-2, and phospho-AKT expression. These results validate the role of CIP2A as a clinically relevant oncoprotein and establish CIP2A as a promising therapeutic target of ovarian cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“High CIP2A expression has been observed in 68-83% of high-grade serous OvCa tumors, and this associates with high proliferation index, aneuploidy, advanced tumor grade, TP53 mutation, and EGFR expression (8,9).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [9]
In the citing paper
“High CIP2A expression has been observed in 68-83% of high-grade serous OvCa tumors, and this associates with high proliferation index, aneuploidy, advanced tumor grade, TP53 mutation, and EGFR expression (8,9).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [9]
In the citing paper
“High CIP2A expression has been observed in 68-83% of high-grade serous OvCa tumors”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [9]
In the citing paper
“and this associates with high proliferation index, aneuploidy, advanced tumor grade, TP53 mutation, and EGFR expression (8,9).”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [9]
In the citing paper
“However, as all the existing data related to CIP2A status in human OvCa is from diagnostic samples (8-10), it is unclear whether CIP2A low tumors exists among the relapsed cases.”
From Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype (2021) · cites this paper as [9]
Citations
Cites
Jemal, A., Siegel, R., Xu, J., & Ward, E. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20073 · Cited by 12,596
Akt/Protein Kinase B Up-regulates Bcl-2 Expression through cAMP-response Element-binding Protein
Pugazhenthi, S., Nesterova, A., Sable, C., Heidenreich, K. A., Boxer, L. M., Heasley, L. E., & Reusch, J. E.-B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.15.10761 · Cited by 679
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 2×
“Consistent with former reports [5, 14], we found that CIP2A depletion caused significant decrease in the proliferation rate and colony formation ability of A2780 and SKOV3 cell lines.”
BackgroundResultSelf-citationSchwartz, D. R., Kardia, S. L. R., Shedden, K., Kuick, R. D., Michailidis, G. C., Taylor, J. M. G., Misek, D. E., WU, R. T., Zhai, Y., Darrah, D. M., et al. (2002) · PubMed · Cited by 430
New Insights Into the Pathogenesis of Serous Ovarian Cancer and Its Clinical Impact
Levanon, K., Crum, C., & Drapkin, R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.1107 · Cited by 412 · cited 1×
“Different tumorigenic pathways have been proposed in the development of low-grade carcinomas (type I) versus high-grade carcinomas (type II), which evolve rapidly, disseminate early, and are highly aggressive [20].”
BackgroundZorn, K. K., Bonome, T., Gangi, L., Chandramouli, G. V. R., Awtrey, C. S., Gardner, G. J., Barrett, J. C., Boyd, J., & Birrer, M. J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0508 · Cited by 376
Cyclin D1: polymorphism, aberrant splicing and cancer risk
Knudsen, K. E., Diehl, J. A., Haiman, C. A., & Knudsen, E. S. (2006) · Oncogene · doi:10.1038/sj.onc.1209371 · Cited by 363
Mateyak, M. K., Obaya, A. J., & Sedivy, J. M. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.4672 · Cited by 331
Epidemiology of Ovarian Cancer
Permuth-Wey, J., & Sellers, T. A. (2009) · Methods in Molecular Biology · doi:10.1007/978-1-60327-492-0_20 · Cited by 326
Therapeutic strategies in epithelial ovarian cancer
Kim, A., Ueda, Y., Naka, T., & Enomoto, T. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-14 · Cited by 319
Cited by
All roads lead to PP 2A: exploiting the therapeutic potential of this phosphatase
Sangodkar, J., Farrington, C. C., McClinch, K., Galsky, M. D., Kastrinsky, D. B., & Narla, G. (2016) · The FEBS Journal · doi:10.1111/febs.13573 · Cited by 312
Liu, C., Hung, M., Wang, D., Chu, P., Su, J.-C., Teng, T.-H., Huang, C., Chao, T.-T., Wang, C., Shiau, C., et al. (2014) · Breast Cancer Research · doi:10.1186/s13058-014-0431-9 · Cited by 120
Kim, J.-S., Kim, E. J., Oh, J. S., Park, I.-C., & Hwang, S.-G. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0888 · Cited by 79
De, P., Carlson, J., Leyland-Jones, B., & Dey, N. (2014) · Oncotarget · doi:10.18632/oncotarget.2127 · Cited by 73
The role of CIP2A in cancer: A review and update
Soofiyani, S. R., Hejazi, M. S., & Baradaran, B. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.146 · Cited by 72
Metadata
- Authors
- Fang, Y., Li, Z., Wang, X., & Zhang, S.
- Affiliations
- Sheng Jing Hospital (CN)
- Corresponding author
- Zhang, Shulan
- Venue
- Tumor Biology
- Published
- 2012-08-25
- Volume
- 33
- Issue
- 6
- Pages
- 2299-2306
- ISSN
- 1010-4283 (ISSN-L)
- 1423-0380
- OpenAlex
- W2046057377
- Semantic Scholar
- dc2411df5636852543a5eb4d8ff74b92183f89c7
- Cited by
- 40
- References
- 28
- Citations by year
- 2025: 4 · 2023: 3 · 2022: 2 · 2021: 2 · 2020: 2 · 2019: 2 · 2017: 4 · 2016: 2 · 2015: 8 · 2014: 6 · 2013: 5
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Tumor Biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Keywords
- CIP2A, ovarian cancer, oncoprotein, protein overexpression, cell proliferation, apoptosis, cell cycle, paclitaxel, cyclin D1, c-Myc, retinoblastoma protein phosphorylation, Bcl-2, Akt, therapeutic target, serous carcinoma, tumor stage and grade
- MeSH terms
- Autoantigens, Adenocarcinoma, Mucinous, Cell Cycle, Colony-Forming Units Assay, Female, Flow Cytometry, Humans, Immunoenzyme Techniques, Membrane Proteins, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Ovarian Neoplasms, Prognosis, RNA, Messenger, Tumor Cells, Cultured, Biomarkers, Tumor, Blotting, Western, Endometrial Neoplasms, Apoptosis, Adenocarcinoma, Clear Cell, Cystadenocarcinoma, Serous, Reverse Transcriptase Polymerase Chain Reaction, Intracellular Signaling Peptides and Proteins, Cell Proliferation, Neoplasm Grading, Real-Time Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. https://app.cochat.ai/papers/10.1007/s13277-012-0492-2
- The paper
- Fang, Y., Li, Z., Wang, X., & Zhang, S. (2012). CIP2A is overexpressed in human ovarian cancer and regulates cell proliferation and apoptosis. Tumor Biology. https://doi.org/10.1007/s13277-012-0492-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.